Diabetes medications may hold unexpected promise for protecting brain health and cognitive function across a spectrum of neurological conditions. This discovery could reshape treatment approaches for millions dealing with depression, dementia, and addiction disorders. A comprehensive analysis spanning 186,847 participants reveals that GLP-1 receptor agonists—originally developed for blood sugar control—demonstrate meaningful improvements in memory and mood regulation. The medications enhanced cognitive performance in patients with Alzheimer's disease, Parkinson's disease, major depression, bipolar disorder, and various substance use conditions. Notably, these cognitive benefits persisted even after discontinuing the treatments, suggesting potential disease-modifying effects rather than temporary symptom relief. Large-scale epidemiological data further indicated that patients receiving these medications experienced reduced incidence of developing mental health disorders altogether. The therapeutic mechanism centers on GLP-1 receptors distributed throughout brain regions critical for cognition and emotional regulation. These same neural pathways implicated in psychiatric conditions respond favorably to receptor activation, explaining the broad therapeutic potential. However, this systematic review primarily synthesizes observational data and smaller clinical studies rather than definitive randomized controlled trials. While the signal appears robust across diverse psychiatric conditions, the field requires large-scale, long-term controlled studies to establish optimal dosing protocols and confirm sustained neuroprotective effects. The convergence of metabolic and psychiatric medicine represents a paradigm shift, suggesting brain health benefits may extend far beyond the cardiovascular and weight management effects currently driving clinical adoption.